Nurix Therapeutics (NRIX) AI Stock Analysis

• Market Cap: $860.06M
• Dividend Yield: N/A
• Average Volume (3M): 866.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.23
• Revenue Growth: 41.86%
• EPS Growth: 10.48%
• Country: US
• Employees: 286
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.52
• Shares Outstanding: 76,449,356
• 10 Day Avg. Volume: 1,222,846
• 30 Day Avg. Volume: 866,177
• PEG Ratio: -0.72
• Price to Book (P/B): 2.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.11
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 3.51
• Enterprise Value/Gross Profit: 24.87
• Enterprise Value/Ebitda: -1.11
• 1Y Price Target: $28.77
• Price Target Upside: 147.38% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 53 Neutral
• Price Target: $11.50 ▼(-1.12%Downside)

Nurix Therapeutics' score reflects its strong equity position and recent positive clinical trial results. However, ongoing profitability and cash flow challenges significantly impact its financial health, and bearish technical indicators further weigh down its overall score. The potential for future growth exists if the company can capitalize on its scientific advancements.

Positive Factors

Collaboration Revenue

Nurix reported $44.1M in collaboration/license revenue, exceeding previous estimates of $25.0M.

Investment Opportunity

Shares remain cheap, and offer an attractive entry point for long-term investors.

Pipeline Progress

Nurix plans to provide additional clinical updates for bexobrutideg and remains on track to initiate pivotal trials in CLL.

Negative Factors

Capital Overhang

There is a capital overhang that needs to be addressed for shares to work meaningfully higher.

Operating Expenses

Analyst slightly lowers the 12-month price target to $34 from $36 due to greater operating expenses.

Regulatory Uncertainty

The stock is not expected to perform well until there is clinical differentiation versus BGB-16673, clarity on a time- and capital-efficient development path, and/or a value-driving strategic partnership.

Nurix Therapeutics Business Overview & Revenue Model

Company Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

How the Company Makes Money

Nurix Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies. These agreements often include upfront payments, research funding, milestone payments, and potential royalties on sales of products developed through joint efforts. The company leverages its proprietary technology platform to engage in partnerships that enhance its drug discovery capabilities and expand its pipeline. Significant collaborations with leading pharmaceutical companies contribute to its earnings and support the ongoing research and development of its therapeutic candidates.

Nurix Therapeutics Financial Statement Overview

Summary

Nurix Therapeutics faces significant challenges in achieving profitability and sustainable cash flow. Despite a strong equity position with minimal leverage, the company struggles with negative net profit and cash flow margins, indicating ongoing operational difficulties.

Income Statement

Nurix Therapeutics has shown an inconsistent revenue trend with notable fluctuations. The TTM data indicates a gross profit margin of 85.39%, reflecting efficient cost management relative to revenue. However, the company is struggling with profitability, as indicated by a negative net profit margin of -369.41%. EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges.

Balance Sheet

The company displays a strong equity position, with an equity ratio of 78.19% in the TTM, indicating low leverage and a strong reliance on equity financing. However, the debt-to-equity ratio stands at 0.06, which is relatively low, suggesting minimal debt use. Return on Equity (ROE) remains negative due to ongoing net losses, impacting overall financial stability.

Cash Flow

Operating cash flow is negative, reflecting ongoing cash burn from operations. The free cash flow growth rate remains concerning, with continued negative figures indicating challenges in generating cash from operations. However, the operating cash flow to net income ratio is slightly improving, suggesting potential operational efficiency gains.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.55M	76.99M	38.63M	29.75M	17.82M
Gross Profit	38.12M	-112.16M	27.82M	23.67M	-48.67M
EBITDA	-196.60M	-141.41M	-173.06M	-111.80M	-62.80M
Net Income	-193.57M	-143.95M	-166.04M	-117.19M	-43.24M
Balance Sheet
Total Assets	669.34M	355.60M	416.76M	476.77M	396.34M
Cash, Cash Equivalents and Short-Term Investments	609.58M	287.91M	309.14M	295.72M	281.15M
Total Debt	28.30M	30.61M	11.96M	13.04M	0.00
Total Liabilities	142.35M	155.10M	113.06M	134.47M	106.07M
Stockholders Equity	526.99M	200.49M	303.70M	342.30M	290.27M
Cash Flow
Free Cash Flow	-181.86M	-89.77M	-172.05M	-90.03M	-4.63M
Operating Cash Flow	-172.58M	-81.36M	-159.81M	-84.36M	-80.00K
Investing Cash Flow	-257.71M	68.30M	27.20M	-108.25M	-254.40M
Financing Cash Flow	485.67M	3.22M	117.19M	153.88M	339.02M

Nurix Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Neutral. The current price of 11.63 is below the 20-day moving average (MA) of 12.05, above the 50-day MA of 11.47, and below the 200-day MA of 16.45, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 47.24 is Neutral, neither overbought nor oversold. The STOCH value of 11.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NRIX.

Nurix Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	61 Neutral	$1.40B	―	-57.92%	―	-13.37%	2.57%
ARVN	57 Neutral	$553.27M	―	-35.41%	―	―	―
RCUS	55 Neutral	$969.91M	―	-63.17%	―	-40.51%	-35.07%
NRIX	53 Neutral	$860.06M	―	-50.67%	―	41.86%	10.48%
MLYS	53 Neutral	$867.48M	―	-56.31%	―	―	-106.10%
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
IOVA	49 Neutral	$1.05B	―	-51.85%	―	11070.12%	32.07%

Nurix Therapeutics Corporate Events

Nurix Therapeutics Announces Positive Phase 1 Trial Results

On June 12, 2025, Nurix Therapeutics announced positive clinical data from its Phase 1 trial of bexobrutideg (NX-5948) at the European Hematology Association Congress. The data showed an objective response rate of 80.9% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 84.2% in patients with Waldenström macroglobulinemia (WM), with bexobrutideg demonstrating a favorable safety profile and potential as a treatment for patients with high unmet medical needs. The company plans to initiate pivotal trials in 2025, reinforcing its scientific leadership in targeted protein degradation.

The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.

Nurix Therapeutics Holds 2025 Annual Stockholders Meeting

On May 19, 2025, Nurix Therapeutics held its virtual 2025 Annual Meeting of Stockholders, where approximately 85.33% of the voting power was represented. Stockholders voted to elect three Class II directors, ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approve the compensation of named executive officers on a non-binding advisory basis.

The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.